The treatment, called blinatumomab, is also in clinical development for the treatment of Non-Hodgkin lymphoma. ❋ Unknown (2012)
The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. ❋ Unknown (2009)
The maker of antibodies and other biologics will manufacture the Bethesda-based biotech's drug, called blinatumomab, for clinical trials. ❋ Unknown (2009)
Amgen highlighted Micromet's lead drug candidate, blinatumomab, an antibody being tested in clinical trials of people with acute lymphoblastic leukemia and non-Hodgkin's lymphoma. ❋ Peter Loftus (2012)
Mr. Perlmutter said results of a small clinical trial of blinatumomab in leukemia, released in December, were promising. ❋ Peter Loftus (2012)
The company said an early study of its antibody blinatumomab treatment for non-Hodgkin's lymphoma has shown high response rates in patients. ❋ Unknown (2009)
These early validations were followed by a clinical validation from clinical trial results from Phase I trial of its drug blinatumomab on non-Hodgkin's lymphoma (NHL) and from Phase II clinical trial results on adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.
This trial builds on the experience of pediatric patients treated with blinatumomab on a compassionate-use basis.
Micromet launched a clinical development program to establish blinatumomab as a key component of treatment for adult and pediatric patients with early and advanced ALL.
In this trial, blinatumomab produced a high complete remission rate with 75% of patients nine of 12 achieving a complete remission and compete remission with partial recovery of blood counts.
"With our lead product candidate blinatumomab expected to begin a European pivotal trial in mid-2010, a clinically validated next-generation antibody platform, and global rights to our two most advanced BiTE antibodies, we believe Micromet is in a strong position to continue to build value for all of our stakeholders in 2010 and beyond," said Christian Itin, Ph. D., ❋ Unknown (2010)
Total operating expenses were $70.4 million for the year ended December 31, 2009, including one-time charges of $6.5 million relating to the acquisition of blinatumomab North American rights, $2.8 million for the purchase of blinatumomab clinical trial material, $4.0 million to settle Curis 'claims and terminate any future payment obligations under the original Curis agreements, and a one-time non-cash patent impairment charge of $2.6 million. ❋ Unknown (2010)
Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab or our other product candidates do not demonstrate safety and/or efficacy in future clinical trials, delays in development and testing, including the risk that we will not obtain approval to market blinatumomab, and the risks associated with reliance on outside financing to meet capital requirements. ❋ Unknown (2010)
One of the company's lead candidates, blinatumomab, successfully completed a Phase II clinical trial in patients with leukemia in the fourth quarter. ❋ Unknown (2010)
- Based on experience from compassionate use utilization of blinatumomab in pediatric patients with relapsed/refractory ALL, the efficacy results in adult ALL and preliminary discussions with the EMEA, the Company is in the process of designing studies to facilitate expedited development of blinatumomab in this setting. ❋ Editors (2010)
Micromet to present new results from its blinatumomab study at the ASH meeting ❋ Editors (2010)
Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009. ❋ Unknown (2010)
These forward-looking statements include statements regarding the development and commercialization of blinatumomab, MT110 and other BiTE antibodies, including the conduct and timing of ongoing and future clinical trials involving these product candidates, the manufacturing of blinatumomab, as well as plans regarding our regulatory strategy and announcements and publication of clinical data. ❋ Unknown (2010)
